Nanomedicines towards targeting intracellular <i>Mtb</i> for the treatment of tuberculosis

Donnellan, Samantha; Giardiello, Marco

doi:10.1002/jin2.61

Cited by 26 publications

(13 citation statements)

References 66 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It used PNs functionalized with the Fc fragment of IgG to target neonatal Fc receptor (FcRn) through an FcRn-mediated transcytosis mechanism so the PNs can finally overstep the intestinal epithelium. Valuable information that may be of interest to the reader have also been reviewed elsewhere regarding nanotherapeutics of leishmaniasis [ 120 , 236 , 237 ], tuberculosis [ 238 , 239 , 240 , 241 , 242 ], viral infections [ 243 , 244 ], HIV [ 245 , 246 , 247 , 248 , 249 ], malaria [ 118 , 250 , 251 , 252 ], infectious diseases [ 4 , 45 , 66 , 253 ], intracellular delivery [ 59 , 60 , 64 , 83 , 254 , 255 ], bacterial pathogens [ 46 , 192 , 256 , 257 , 258 , 259 ] and stimuli-responsive systems [ 15 , 58 , 260 , 261 , 262 ].…”

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

2020

View full text Add to dashboard Cite

Polymeric nanocarriers (PNs) have demonstrated to be a promising alternative to treat intracellular infections. They have outstanding performance in delivering antimicrobials intracellularly to reach an adequate dose level and improve their therapeutic efficacy. PNs offer opportunities for preventing unwanted drug interactions and degradation before reaching the target cell of tissue and thus decreasing the development of resistance in microorganisms. The use of PNs has the potential to reduce the dose and adverse side effects, providing better efficiency and effectiveness of therapeutic regimens, especially in drugs having high toxicity, low solubility in the physiological environment and low bioavailability. This review provides an overview of nanoparticles made of different polymeric precursors and the main methodologies to nanofabricate platforms of tuned physicochemical and morphological properties and surface chemistry for controlled release of antimicrobials in the target. It highlights the versatility of these nanosystems and their challenges and opportunities to deliver antimicrobial drugs to treat intracellular infections and mentions nanotoxicology aspects and future outlooks.

show abstract

Section: Recent Advances Of Pns In the Treatment Of Intracellular mentioning

confidence: 99%

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, these studies present promising results with cases of activity reported against MDR and XDR strains [ 19 , 26 , 71 , 72 , 78 ], as well as activity against intracellular MTb [ 56 , 73 ]. This is especially relevant for latent TB where MTb remain inside granulomas [ 79 ], where they adapt and thrive under adverse conditions, such as nutrient deprivation and hypoxia [ 3 ].…”

Section: Resultsmentioning

confidence: 99%

Mycogenic Metal Nanoparticles for the Treatment of Mycobacterioses

2020

View full text Add to dashboard Cite

Mycobacterial infections are a resurgent and increasingly relevant problem. Within these, tuberculosis (TB) is particularly worrying as it is one of the top ten causes of death in the world and is the infectious disease that causes the highest number of deaths. A further concern is the on-going emergence of antimicrobial resistance, which seriously limits treatment. The COVID-19 pandemic has worsened current circumstances and future infections will be more incident. It is urgent to plan, draw solutions, and act to mitigate these issues, namely by exploring new approaches. The aims of this review are to showcase the extensive research and application of silver nanoparticles (AgNPs) and other metal nanoparticles (MNPs) as antimicrobial agents. We highlight the advantages of mycogenic synthesis, and report on their underexplored potential as agents in the fight against all mycobacterioses (non-tuberculous mycobacterial infections as well as TB). We propose further exploration of this field.

show abstract

“…Plenty of studies demonstrate the in vitro and in vivo achievements of using passively targeted nanocarriers against TB as reviewed recently. [12,13,[48][49][50][51][52][53][54] Most in vitro experimental models of TB infection for studying effects of nanocarriers use primary macrophages, macrophage-like immortalized cell lines, and induced pluripotent-stem-cell-derived macrophages. In vitro granuloma model based on human peripheral blood mononuclear cells (PBMCs) represents a more complex system.…”

Section: Passive Targetingmentioning

confidence: 99%

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Baranyai

Soria‐Carrera

Alleva

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial‐loaded nanocarriers are avidly taken up by macrophages, the main cells hosting Mycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment.

show abstract

Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis

Cited by 26 publications

References 66 publications

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

Mycogenic Metal Nanoparticles for the Treatment of Mycobacterioses

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Contact Info

Product

Resources

About